Trial Profile
A phase I study investigating AIC-649 in patients with chronic hepatitis B
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Sep 2019
Price :
$35
*
At a glance
- Drugs AIC 649 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors AiCuris
- 03 Sep 2018 Status changed from recruiting to completed, according to an AiCuris media release.
- 03 Sep 2018 Results presented in an AiCuris media release.
- 24 Oct 2017 According to an AiCuris media release, results shall be announced in early 2018.